To request a free sample copy of this report, please complete the form below.
What people say about us!

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

logos logos logos logos logos
Analyst Support
$5,300
BUY NOW
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Sepsis Diagnostics Market size was valued at USD 0.67 billion in 2022 and is poised to grow from USD 0.74 billion in 2023 to USD 1.55 billion by 2031, growing at a CAGR of 9.8% during the forecast period (2024-2031). 

The sepsis diagnostic market is highly competitive, with several established players competing for market share. These companies are investing heavily in R&D activities to develop technologically advanced diagnostic solutions and gain a competitive edge. Moreover, strategic partnerships and collaborations with other companies and healthcare facilities are commonly observed in the market. Additionally, companies are focusing on expanding their geographic presence through acquisitions, partnerships, and collaborations. Furthermore, product launches, regulatory approvals, and patent filings are among the key strategies adopted by companies to strengthen their market position. 'Abbott Laboratories (US)', 'Becton, Dickinson and Company (US)', 'bioMérieux SA (France)', 'Cepheid (US)', 'F. Hoffmann-La Roche AG (Switzerland)', 'Hologic Inc. (US)', 'Imbio LLC (US)', 'Luminex Corporation (US)', 'MedMira Inc. (Canada)', 'Meridian Bioscience, Inc. (US)', 'Nanosphere (US)', 'QIAGEN N.V. (Netherlands)', 'Thermo Fisher Scientific Inc. (US)', 'T2 Biosystems, Inc. (US)', 'Biomarck Pharmaceuticals Ltd. (UK)', 'Magnitude Biosciences (US)', 'Axis-Shield Diagnostics Ltd. (UK)', 'Biocartis Group NV (Belgium)', 'Inflammatix Inc. (US)', 'OpGen, Inc. (US)'

One of the key market trends in the sepsis diagnostic market is the increasing adoption of point-of-care (POC) testing. POC tests are designed to provide rapid and accurate diagnosis of sepsis, which can significantly improve patient outcomes. POC tests are portable, easy-to-use, and can be conducted outside the traditional laboratory setting, making them ideal for use in emergency rooms, ambulances, and critical care units. The demand for POC tests is expected to increase over the forecast period, driven by the need for rapid diagnosis and the growing adoption of digital health technologies.

North America dominated the sepsis diagnostic market due to the increasing incidence of sepsis and hospital-acquired infections, coupled with the presence of leading market players and advanced healthcare infrastructure. The US and Canada are the major contributors to the growth of the market in this region. In addition, the increasing awareness about sepsis and the availability of advanced diagnostic solutions are also driving the growth of the market in North America.

Feedback From Our Clients

Global Sepsis Diagnostics Market

Product ID: SQMIG35A2237

$5,300
BUY NOW